Induction of protective immunity against experimental infection with malaria using synthetic peptides.
about
IMPIPS: the immune protection-inducing protein structure concept in the search for steric-electron and topochemical principles for complete fully-protective chemically synthesised vaccine developmentA mimotope peptide-based vaccine against Schistosoma mansoni: synthesis and characterization.MSP-1 malaria pseudopeptide analogs: biological and immunological significance and three-dimensional structure.Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus.Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines.Synthesis and characterization of a protective peptide-based vaccine against Schistosoma mansoniContributions of mass spectrometry to structural immunology.Current status of malaria and potential for control.High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria.Characterization of conserved T- and B-cell epitopes in Plasmodium falciparum major merozoite surface protein 1.Inhibition of bacterial superantigens by peptides and antibodiesFamilial correlation of immunoglobulin G subclass responses to Plasmodium falciparum antigens in Burkina Faso.Rhoptry-associated protein 1-binding monoclonal antibody raised against a heterologous peptide sequence inhibits Plasmodium falciparum growth in vitroImmunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii.Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro.Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparumChemokine levels and parasite- and allergen-specific antibody responses in children and adults with severe or uncomplicated Plasmodium falciparum malariaCytokines and antibody subclass associated with protective immunity against blood-stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant.NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.Conservation of Babesia bovis small heat shock protein (Hsp20) among strains and definition of T helper cell epitopes recognized by cattle with diverse major histocompatibility complex class II haplotypes.Cellular and humoral immune responses to well-defined blood stage antigens (major merozoite surface antigen) of Plasmodium falciparum in adults from an Indian zone where malaria is endemic.Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines.Allelic forms of gp195, a major blood-stage antigen of Plasmodium falciparum, are expressed in liver stagesRoles of conserved and allelic regions of the major merozoite surface protein (gp195) in immunity against Plasmodium falciparum.Effects of transmission-blocking vaccines simultaneously targeting pre- and post-fertilization antigens in the rodent malaria parasite Plasmodium yoelii.Murine infection models for vaccine development: the malaria example.The conformational restriction of synthetic vaccines for malaria.Towards the development of a fully protective Plasmodium falciparum antimalarial vaccine.Recent advances in the development of a chemically synthesised anti-malarial vaccine.An update on candidate malaria vaccines.Mechanisms of immunity to malaria and the possibilities of a blood-stage vaccine: a critical appraisal.Protection of squirrel monkeys against virulent Plasmodium falciparum infections by use of attenuated parasites.Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission.Heritability and segregation analysis of immune responses to specific malaria antigens in Papua New Guinea.Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys.Sharing of antigens between Plasmodium falciparum and Anopheles albimanus.In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system.Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins.
P2860
Q30373743-D55C1434-07AB-4D42-97F0-3438A03E29A2Q30976913-93D509AB-36A1-4706-A1F3-85A184E28FA4Q31137274-2773CA88-2DBF-43CD-9E9B-53E193A6B537Q33605280-F06716A4-945B-4913-B970-69086AF94975Q33757015-7065E303-4B18-4AC8-BAF7-8CD73325D566Q33763564-39F2512B-A775-4383-AE04-9CDED328FA35Q33910650-63242787-895D-41EA-8D84-7A76898189A8Q33975652-F0EEBAA5-57A4-4E32-81C5-10DAF926D33FQ34003525-8860ECB0-26A5-4D66-A1C7-9340E908BE0DQ34004267-177A7541-2D9E-476C-A35C-608BB1A2DD74Q34005961-642E1848-487D-4401-BD0E-81E84C079787Q34006021-49BF7E70-801E-4585-B929-826F55560606Q34006980-B2A55D97-EAAF-4D12-91F7-908200360A80Q34258733-0C999FC1-3DF7-429B-A68F-FD8728BCCB3AQ34541366-DA23EF4B-1B61-4ABC-9D34-A844CD509F5CQ35383761-02364A6D-E0AA-49F5-8D92-C69CBCA39661Q35426918-3C6E46C2-6935-4E49-B255-D91F5C0FE1FEQ35515912-963A163D-6564-464E-B820-07BDB8CD4053Q35519418-42C27652-5ED9-4CBE-B72B-59C4683517C5Q35551115-B97BEEE9-B366-4DEC-98D8-C2B624B3C446Q35773738-1C8439BF-F32A-47DE-8A82-1670C56FF9A5Q35862464-AFC5DA15-C416-44C1-8D3B-D1926BC4F3DFQ36354328-820352E3-9322-4738-BC1F-B09ECC9C14F3Q36943106-21605123-8D1B-47FA-AAFF-3121E2947B54Q37160241-352A2AF5-75EA-43D8-BB60-C8F0908C8260Q37478246-3889CB16-C881-41AD-9CCB-B651343CAF00Q37800088-DBF552DC-D87C-4F07-8D82-E92B916D4E7CQ38059750-551E641F-448F-4344-A817-FA4831D2C373Q38560128-83B01B89-259F-4062-980A-5E935E3B470AQ38635546-EACFC0D5-DFEE-4283-825D-3763851F912AQ38674929-408DF1B7-349B-4032-98FE-EA77168DCC7EQ38890360-1AC75029-FE04-4C67-8F0C-9BA0F8C5D6EAQ39372910-57883A1D-4EAB-4386-93D2-B05ACB213A3BQ39387268-7F437D57-2B22-4116-B076-D873B4BE9D5EQ39491568-4D06B722-C36C-4C37-B100-A8537F359F17Q39572070-5C787948-2177-478F-9715-D8342353B28CQ39591450-065F193F-BD6E-44D7-8A56-A3CB8385A08FQ39655089-626162EB-77AE-4516-AD22-C6B32BC322A7Q39881434-8909B894-86A9-4113-B5BE-F3A26C9CDB60Q40146914-4FF9309B-EF0A-4BC0-9622-60FB0DC5DD94
P2860
Induction of protective immunity against experimental infection with malaria using synthetic peptides.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Induction of protective immuni ...... aria using synthetic peptides.
@en
Induction of protective immuni ...... aria using synthetic peptides.
@nl
type
label
Induction of protective immuni ...... aria using synthetic peptides.
@en
Induction of protective immuni ...... aria using synthetic peptides.
@nl
prefLabel
Induction of protective immuni ...... aria using synthetic peptides.
@en
Induction of protective immuni ...... aria using synthetic peptides.
@nl
P2093
P356
P1433
P1476
Induction of protective immuni ...... aria using synthetic peptides.
@en
P2093
Martínez A
Patarroyo ME
Rodríguez R
P2888
P304
P356
10.1038/328629A0
P407
P577
1987-08-01T00:00:00Z
P6179
1013246316